What was lost in translation in the DHA trial is whom you should intend to treat

Alzheimer's Research and Therapy

Volumn 3, Issue 1, 2011, Pages

  Frautschy, Sally A ^a,b   Cole, Greg M ^a,b  

^a GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN E4; BETA AMYLASE; DOCOSAHEXAENOIC ACID; LIPID PEROXIDE; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG MEGADOSE; IN VIVO CULTURE; IN VIVO STUDY; LIPID BLOOD LEVEL; LIPID PEROXIDATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VITAMIN BLOOD LEVEL;

EID: 84856298512     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt61     Document Type: Review

References (18)

1. DHA may prevent age-related dementia. GM Cole, SA Frautschy, J Nutr 2010 140 869 874 10.3945/jn.109.113910 20181786
2. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JF Quinn, R Raman, RG Thomas, K Yurko-Mauro, EB Nelson, C Van Dyck, JE Galvin, J Emond, CR Jack Jr, M Weiner, L Shinto, PS Aisen, JAMA 2010 304 1903 1911 10.1001/jama.2010.1510 21045096
3. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Y Freund-Levi, M Eriksdotter-Jonhagen, T Cederholm, H Basun, G Faxen-Irving, A Garlind, I Vedin, B Vessby, LO Wahlund, J Palmblad, Arch Neurol 2006 63 1402 1408 10.1001/archneur.63.10.1402 17030655 (Pubitemid 44547551)
4. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. CC Chiu, KP Su, TC Cheng, HC Liu, CJ Chang, ME Dewey, R Stewart, SY Huang, Prog Neuropsychopharmacol Biol Psychiatry 2008 32 1538 1544 10.1016/j.pnpbp.2008.05.015 18573585
5. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. S Kotani, E Sakaguchi, S Warashina, N Matsukawa, Y Ishikura, Y Kiso, M Sakakibara, T Yoshimoto, J Guo, T Yamashima, Neurosci Res 2006 56 159 164 10.1016/j.neures.2006.06.010 16905216 (Pubitemid 44374788)
6. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. EJ Johnson, K McDonald, SM Caldarella, HY Chung, AM Troen, DM Snodderly, Nutr Neurosci 2008 11 75 83 10.1179/ 147683008X301450 18510807
7. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. K Yurko-Mauro, D McCarthy, D Rom, EB Nelson, AS Ryan, A Blackwell, N Salem Jr, M Stedman, M Investigators, Alzheimers Dement 2010 6 456 464 10.1016/j.jalz.2010.01.013 20434961
8. Effect of fish oil on cognitive performance in older subjects: a randomized controlled trial. O Van de Rest, J Geleijnse, F Kok, W van Staveren, C Dullemeijer, M OldeRikkert, A Beekman, L de Groot, Neurology 2008 71 430 438 10.1212/01.wnl.0000324268.45138.86 18678826
9. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. AD Dangour, E Allen, D Elbourne, N Fasey, AE Fletcher, P Hardy, GE Holder, R Knight, L Letley, M Richards, R Uauy, Am J Clin Nutr 2010 91 1725 1732 10.3945/ajcn.2009.29121 20410089
10. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. GP Lim, F Calon, T Morihara, F Yang, B Teter, O Ubeda, N Salem Jr, SA Frautschy, GM Cole, J Neurosci 2005 25 3032 3040 10.1523/JNEUROSCI.4225-04.2005 15788759 (Pubitemid 40463537)
11. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. F Calon, GP Lim, F Yang, T Morihara, B Teter, O Ubeda, P Rostaing, A Triller, N Salem Jr, KH Ashe, SA Frautschy, GM Cole, Neuron 2004 43 633 645 10.1016/j.neuron.2004.08.013 15339646 (Pubitemid 39179724)
12. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. SE Counts, M Nadeem, SP Lad, J Wuu, EJ Mufson, J Neuropathol Exp Neurol 2006 65 592 601 10.1097/00005072-200606000-00007 16783169 (Pubitemid 44288943)
13. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. KN Green, H Martinez-Coria, H Khashwji, EB Hall, KA Yurko-Mauro, L Ellis, FM LaFerla, J Neurosci 2007 27 4385 4395 10.1523/JNEUROSCI.0055-07.2007 17442823 (Pubitemid 46640724)
14. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. QL Ma, F Yang, ER Rosario, OJ Ubeda, W Beech, DJ Gant, PP Chen, B Hudspeth, C Chen, Y Zhao, HV Vinters, SA Frautschy, GM Cole, J Neurosci 2009 29 9078 9089 10.1523/JNEUROSCI.1071-09.2009 19605645
15. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. MA Reger, GS Watson, PS Green, LD Baker, B Cholerton, MA Fishel, SR Plymate, MM Cherrier, GD Schellenberg, WH Frey, S Craft, J Alzheimers Dis 2008 13 323 331 18430999 (Pubitemid 352039034)
16. n-3 fatty acids induce oxidative modifications in human erythrocytes depending on dose and duration of dietary supplementation. P Palozza, E Sgarlata, C Luberto, E Piccioni, M Anti, G Marra, F Armelao, P Franceschelli, GM Bartoli, Am J Clin Nutr 1996 64 297 304 8780337 (Pubitemid 26287316)
17. Lipid peroxidation during n-3 fatty acid and vitamin E supplementation in humans. JP Allard, R Kurian, E Aghdassi, R Muggli, D Royall, Lipids 1997 32 535 541 10.1007/s11745-997-0068-2 9168460 (Pubitemid 27213324)
18. Lipid peroxidation products are elevated in fish oil diets even in the presence of added antioxidants. MJ Gonzalez, JI Gray, RA Schemmel, L Dugan Jr, CW Welsch, J Nutr 1992 122 2190 2195 1432259